Lancet Neurology Publishes Pivotal Phase III Data Supporting Zonegran® (Zonisamide) as a Once-Daily Monotherapy for Newly Diagnosed Partial Onset Epilepsy Patients

Lancet Neurology Publishes Pivotal Phase III Data Supporting Zonegran® (Zonisamide) as a Once-Daily Monotherapy for Newly Diagnosed Partial Onset Epilepsy Patients PR Newswire HATFIELD, England, June 27, 2012 HATFIELD, England, June 27, 2012 /PRNewswire/ -- New monotherapy options are needed as up to a third of epilepsy [1]patients remain uncontrolled Leading international journal, The Lancet Neurology, today published positive ®results from a new pivotal Phase III Zonegran (zonisamide) monotherapy study showing that once-daily zonisamide is non-inferior to controlled-release ®carbamazepine (Tegretol retard) and could prove to be a useful initial [2]monotherapy for newly diagnosed partial onset epilepsy patients Carbamazepine is the most well-established monotherapy comparator for patients newly diagnosed with partial onset seizures (the most common type of [2]epilepsy). Commenting on the results, Professor Michel Baulac, manuscript lead author and head of the clinical department at the Hospital de la Pitie-Salpetriere, Paris, France said; "These data will be of key interest to general neurologists and epileptologists across Europe as they demonstrate that zonisamide is effective and non-inferior to the standard first line monotherapy. It is essential to ensure newly diagnosed epilepsy patients achieve adequate seizure control, so a potential new and effective monotherapy treatment option is very exciting.